We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+132.32%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$691M
AUM Growth
+$202M
(+41%)
Cap. Flow
+$28.6M
Cap. Flow
% of AUM
4.14%
Top 10 Holdings %
Top 10 Hldgs %
46.73%
Holding
91
New
27
Increased
28
Reduced
16
Closed
11
Top Buys
| 1 |
ABVX
Abivax
ABVX
|
+$33.1M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$17.6M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$14.8M |
| 4 |
Fractyl Health
GUTS
|
+$13.5M |
| 5 |
Biogen
BIIB
|
+$10.9M |
Top Sells
| 1 |
MRUS
Merus
MRUS
|
+$39M |
| 2 |
VRNA
Verona Pharma
VRNA
|
+$33.9M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$20.5M |
| 4 |
ETNB
89bio
ETNB
|
+$20M |
| 5 |
SLNO
Soleno Therapeutics
SLNO
|
+$17.1M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$11.9B
| $45.8M | 6.63% |
+539,704
| New | +$33.1M |
|
2
Rhythm Pharmaceuticals
RYTM
$7.42B
| $37.4M | 5.41% |
369,996
-30,776
| -8% | -$2.86M |
|
|
RNAM
3
DELISTED
Avidity Biosciences
RNAM
| $36.8M | 5.33% |
844,633
+434,633
| +106% | +$17.6M |
|
4
Nuvalent
NUVL
$9.81B
| $32.2M | 4.66% |
372,300
+136,717
| +58% | +$10.8M |
|
5
UroGen Pharma
URGN
$1.88B
| $31.5M | 4.56% |
1,577,283
-445,199
| -22% | -$7.99M |
|
|
AKRO
6
DELISTED
Akero Therapeutics
AKRO
| $30.6M | 4.42% |
643,636
-70,175
| -10% | -$3.4M |
|
7
Insmed
INSM
$23.5B
| $29.8M | 4.31% |
206,648
-42,412
| -17% | -$5.2M |
|
|
8
Dianthus Therapeutics
DNTH
$5.54B
| $26.6M | 3.85% |
674,966
+579,160
| +605% | +$14.8M |
|
9
uniQure
QURE
$2.83B
| $26.6M | 3.85% |
455,000
+252,435
| +125% | +$4.58M |
|
10
CG Oncology
CGON
$6.43B
| $25.7M | 3.72% |
638,346
+97,312
| +18% | +$2.83M |
|
11
Oric Pharmaceuticals
ORIC
$1.11B
| $23.4M | 3.39% |
1,948,808
+147,979
| +8% | +$1.56M |
|
|
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
| $21.2M | 3.06% |
220,902
+116,959
| +113% | +$7.46M |
|
|
13
Fractyl Health
GUTS
$136M
| $16.9M | 2.44% |
10,600,000
+10,397,410
| +5,132% | +$13.5M |
|
|
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
| $16.6M | 2.4% |
1,363,378
-468,793
| -26% | -$6.48M |
|
15
Kodiak Sciences
KOD
$2.61B
| $16.4M | 2.37% |
1,000,000
+598,460
| +149% | +$5.16M |
|
16
Gossamer Bio
GOSS
$65M
| $12.6M | 1.82% |
4,779,082
-367,700
| -7% | -$810K |
|
17
Cogent Biosciences
COGT
$6.57B
| $11.7M | 1.69% |
+815,075
| New | +$9.66M |
|
18
Cytokinetics
CYTK
$11.1B
| $11.6M | 1.68% |
+211,000
| New | +$8.69M |
|
19
Vaxcyte
PCVX
$8.06B
| $11.3M | 1.64% |
314,339
+26,543
| +9% | +$879K |
|
|
20
Biogen
BIIB
$28.1B
| $11.3M | 1.63% |
+80,419
| New | +$10.9M |
|
21
Ascendis Pharma A/S
ASND
$17.4B
| $10.6M | 1.54% |
53,554
-32,998
| -38% | -$6.15M |
|
22
Compass Therapeutics
CMPX
$387M
| $9.92M | 1.44% |
2,833,988
+1,584,207
| +127% | +$5M |
|
23
Amylyx Pharmaceuticals
AMLX
$1.96B
| $9.51M | 1.38% |
+700,000
| New | +$6.59M |
|
24
Verastem
VSTM
$467M
| $9.21M | 1.33% |
+1,042,757
| New | +$7.76M |
|
25
Avalo Therapeutics
AVTX
$972M
| $9.16M | 1.33% |
+720,922
| New | +$6.2M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA